I am long CYDY. It is my opinion that we do not
Post# of 148337
(Total Views: 599)
Posted On: 05/11/2020 6:03:15 PM
I am long CYDY.
It is my opinion that we do not know well Leronlimb works until it is compared to a placebo arm. Much confidence is being assumed from the 88% mortality referenced in the Patterson pre-publish. But the 88% is apparently not a reliable statistic:
https://www.poynter.org/fact-checking/2020/re...d-context/
For severe cases, remember that widely published study for Remdesivir and placebo for severe patients has a 8-11% mortality, so even if two patients out of the 23 patients at UCLA die in the EIND on severe patients, then it may be confusing I am saying this because the report on those patients said some were still in the hospital and several were not showing improvement. However, many of these patients probably have more complications than in the Remdesivir cohort. So, it's messy.
I am hopeful because of the consistent blood work trends in the Patterson paper. This shows some sound reasoning behind why it should work.
It is my opinion that we do not know well Leronlimb works until it is compared to a placebo arm. Much confidence is being assumed from the 88% mortality referenced in the Patterson pre-publish. But the 88% is apparently not a reliable statistic:
https://www.poynter.org/fact-checking/2020/re...d-context/
For severe cases, remember that widely published study for Remdesivir and placebo for severe patients has a 8-11% mortality, so even if two patients out of the 23 patients at UCLA die in the EIND on severe patients, then it may be confusing I am saying this because the report on those patients said some were still in the hospital and several were not showing improvement. However, many of these patients probably have more complications than in the Remdesivir cohort. So, it's messy.
I am hopeful because of the consistent blood work trends in the Patterson paper. This shows some sound reasoning behind why it should work.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼